MY137089A - Materials and methods relating to protein aggregation in neurodegenerative disease - Google Patents

Materials and methods relating to protein aggregation in neurodegenerative disease

Info

Publication number
MY137089A
MY137089A MYPI20032479A MY137089A MY 137089 A MY137089 A MY 137089A MY PI20032479 A MYPI20032479 A MY PI20032479A MY 137089 A MY137089 A MY 137089A
Authority
MY
Malaysia
Prior art keywords
precursor protein
fragment
cell
materials
protein
Prior art date
Application number
Inventor
Wischik Claude Michel
Horsley David
Rickard Janet Elizabeth
Harrington Charles Robert
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Priority to MYPI20032479 priority Critical patent/MY137089A/en
Publication of MY137089A publication Critical patent/MY137089A/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DISCLOSED ARE METHODS OF PROTEOLYTICALLY CONVERTING A PRECURSOR PROTEIN (E.G. TAU) TO A PRODUCT FRAGMENT (E.G. A 12 KD FRAGMENT) IN A STABLE CELL LINE, WHEREIN THE PRECURSOR PROTEIN IS ASSOCIATED WITH A DISEASE STATE IN WHICH THE PRECURSOR PROTEIN AGGREGATES PATHOLOGICALLY (E.G. A TAUOPATHY), AND THE METHODS COMPRISE: (A) PROVIDING A STABLE CELL LINE TRANSFECTED WITH NUCLEIC ACID ENCODING: (I) A TEMPLATE FRAGMENT OF THE PRECURSOR PROTEIN SUCH THAT THE TEMPLATE FRAGMENT IS CONSTITUTIVELY EXPRESSED IN THE CELL AT A LEVEL WHICH IS NOT TOXIC TO THE CELL; AND (II) THE PRECURSOR PROTEIN, WHICH PROTEIN IS INDUCIBLY EXPRESSED IN THE CELL IN RESPONSE TO A STIMULUS, WHEREBY INTERACTION OF THE TEMPLATE FRAGMENT WITH THE PRECURSOR PROTEIN CAUSES A CONFORMATIONAL CHANGE IN THE PRECURSOR PROTEIN SUCH AS TO CAUSE AGGREGATION AND PROTEOLYTIC PROCESSING OF THE PRECURSOR PROTEIN TO THE PRODUCT FRAGMENT. THE METHOD IS PREFERABLY USED TO SCREEN FOR MODULATORS OF THE AGGREGATION PROCESS BY MONITORING PRODUCTION (OR MODULATION OF PRODUCTION) OF THE PRODUCT BAND OR BANDS. ALSO PROVIDED ARE MATERIALS FOR USED IN THE ASSAYS, PLUS MEDICAMENTS, AND RELATED USES AND PROCESSES, BASED ON COMPOUNDS WHICH SHOW HIGH ACTIVITY IN THE ASSAY OF THE INVENTION E.G. REDUCED DIAMINOPHENOTHIAZINES.
MYPI20032479 2003-07-01 2003-07-01 Materials and methods relating to protein aggregation in neurodegenerative disease MY137089A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI20032479 MY137089A (en) 2003-07-01 2003-07-01 Materials and methods relating to protein aggregation in neurodegenerative disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20032479 MY137089A (en) 2003-07-01 2003-07-01 Materials and methods relating to protein aggregation in neurodegenerative disease

Publications (1)

Publication Number Publication Date
MY137089A true MY137089A (en) 2008-12-31

Family

ID=45893945

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20032479 MY137089A (en) 2003-07-01 2003-07-01 Materials and methods relating to protein aggregation in neurodegenerative disease

Country Status (1)

Country Link
MY (1) MY137089A (en)

Similar Documents

Publication Publication Date Title
HK1149588A1 (en) Materials and methods relating to protein aggregation in neurodegenerative disease
DE50302840D1 (en) PROCESS FOR THE PREPARATION OF ARYL-ARYL COUPLED COMPOUNDS
TR200201094T2 (en) Bicyclic amino acids as pharmaceuticals
ATE334218T1 (en) METHOD FOR THE SIMULTANEOUS PRODUCTION OF XYLITOL AND ETHANOL
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
MXPA04006082A (en) Malleable protein matrix and uses thereof.
DE50313162D1 (en) INTEGRATED PROCESS FOR THE PREPARATION OF ISOCYANATES
DE69117949D1 (en) PROTEIN ASSOCIATED WITH ACUTE PANCREATITIS, MEANS FOR DIAGNOSIS OF ACUTE PANCREATITIS
TW200505505A (en) Process for modifying drug crystal formation
ATE260096T1 (en) AGGLOMERATES BY CRYSTALIZATION
BRPI0416672A (en) method of producing a lecithin-containing granular composition and lecithin-containing granular composition
ES2106772T3 (en) PAI-2 VARIANTS.
ATE311476T1 (en) POLYMORPHISMS IN THE HUMAN ORGANIC ANION TRANSPORTER C (OATP-C) GENE
MY137089A (en) Materials and methods relating to protein aggregation in neurodegenerative disease
WO2003004681A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
BR9913720A (en) Purification process by crystallization or crystallization of carboxylic acids
ATE539051T1 (en) METHOD FOR PRODUCING N-METHYL PYRROLIDONE USING GAMMA BUTYROLACTONE AND MIXED METHYLAMINES AS STARTING SUBSTANCES
ATE435291T1 (en) ALLELES OF THE GLUCOCINASE GENE OF CORYNEFORM BACTERIA
MXPA05011157A (en) A novel method of modulating bone-realted activity.
WO2004013122A3 (en) Octupolar molecules used as organic semi-conductors
HUP9701747A2 (en) Process for producing zeolites from raw materials containing alkaline-aluminium-hydrosilicate
TWI346654B (en) Process for the purification of hexamethylenediamine
PL1664087T3 (en) Prion clearance using particulate metal oxides
DE69919558D1 (en) USE OF SOCS-2 OR CIS TO 'SCREEN' SUBSTANCES THAT ENHANCE A GROWTH HORMONE EFFECT
ATE180478T1 (en) USE OF SUBSTITUTED 6-AMINO-4H-PYRANES